Ceftriaxone (3rd generation cephalosporin) plus Tazobactam (β-lactamase inhibitor) produces rapid reduction in bacterial load when administered immediately after infection.
Ceftriaxone 250 mg + Tazobactam 31.25 mg
Adults: 1–2 g once daily (max 4 g/day)
Pediatrics: 50–75 mg/kg/day (not > 1 g/day)
GI upset 2–3%, rash 1–3%, hematological 1–2%, others 1.5–3%; rare acute anaphylaxis in susceptible adults.
Not recommended in pregnancy; caution in nursing mothers; avoid in hyperbilirubinemic neonates (especially premature).
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Combination of Ceftriaxone and Tazobactam ensures broad-spectrum activity including β-lactamase–producing organisms for effective infection control.
Ceftriaxone 500 mg + Tazobactam 62.5 mg
Adults: 1–2 g once daily (max 4 g/day)
Pediatrics: 50–75 mg/kg/day (not > 1 g/day)
GI upset, rash, mild hematological changes; rare anaphylaxis possible.
Avoid in pregnancy; caution in lactation; contraindicated in hyperbilirubinemic neonates.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
High-strength Ceftriaxone + Tazobactam formulation for severe infections requiring aggressive broad-spectrum treatment including β-lactamase–resistant strains.
Ceftriaxone 1000 mg + Tazobactam 125 mg
Adults: 1–2 g once daily (max 4 g/day)
Pediatrics: 50–75 mg/kg/day (not > 1 g/day)
GI effects, rash, hematologic changes; rare anaphylaxis in hypersensitive patients.
Not recommended in pregnancy; avoid in hyperbilirubinemic neonates; use caution in nursing mothers.
Strip of 10 tablets.
“For Healthcare Professionals & Business Partners Only”
Company Identification Number
( CIN ) : U24230MH1975PLC018296
Medley House, D2,
M.I.D.C. Area,
Andheri (East),
Mumbai-400 093, INDIA